INNOVATE Corp. (VATE)

NYSE: VATE · Real-Time Price · USD
11.76
-0.26 (-2.20%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Market Cap170.56M +107.5%
Revenue (ttm)1.25B +12.5%
Net Income-64.00M
EPS-4.84
Shares Out 13.65M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume34,916
Open12.34
Previous Close12.02
Day's Range11.75 - 12.44
52-Week Range3.75 - 13.34
Beta1.54
Analystsn/a
Price Targetn/a
Earnings DateMay 14, 2026

About VATE

INNOVATE Corp., through its subsidiaries, operates in infrastructure, life sciences, and spectrum areas in the United States. The company operates through the Infrastructure, Life Sciences, and Spectrum segments. The Infrastructure segment provides industrial construction, structural steel, and facility maintenance services, such as fabrication and erection of structural steel and heavy steel plate services, and large-diameter water pipes and water storage tanks; fabrication of trusses and girders; 3-D building information modeling and detailin... [Read more]

IPO Date Nov 7, 1996
Employees 3,738
Stock Exchange NYSE
Ticker Symbol VATE
Full Company Profile

Financial Performance

In 2025, INNOVATE's revenue was $1.25 billion, an increase of 12.55% compared to the previous year's $1.11 billion. Losses were -$64.00 million, 78.8% more than in 2024.

Financial Statements

News

INNOVATE Corp. to Report First Quarter 2026 Results on May 14th

NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that it will release its financial results for the first quarter 2026 on Thursday...

23 hours ago - GlobeNewsWire

INNOVATE's Portfolio Company DBM Global to Pay Cash Dividend

NEW YORK, April 06, 2026 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that DBM Global Inc. (“DBMG”), a family of companies providing fully integrated s...

22 days ago - GlobeNewsWire

MediBeacon® Transdermal GFR Monitor and Reusable Sensor Receive CE Mark Under European Medical Device Regulation

NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that MediBeacon Inc. (“MediBeacon”), a medical technology company specializing in...

4 weeks ago - GlobeNewsWire

INNOVATE Earnings Call Transcript: Q4 2025

Fourth quarter revenue surged 61.7% year-over-year, driven by infrastructure, while net loss narrowed. Life sciences and spectrum segments faced headwinds, but regulatory wins and backlog growth position the company for 2026 expansion.

4 weeks ago - Transcripts

INNOVATE Corp. Announces Fourth Quarter and Full Year 2025 Results

- Infrastructure: NYC and Western markets continue to demonstrate positive project momentum - - Life Sciences: R2 Secures 600‑System Commitment in China - - Spectrum: Recent network launches set to de...

4 weeks ago - GlobeNewsWire

INNOVATE Corp. to Report Fourth Quarter and Full Year 2025 Results on March 26th

NEW YORK, March 16, 2026 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that it will release its financial results for the fourth quarter and full year 2...

6 weeks ago - GlobeNewsWire

Transdermal GFR Article Recognized as One of Five 2025 Editors' Choice Articles by Journal of the American Society of Nephrology (JASN)

NEW YORK, Feb. 10, 2026 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that MediBeacon Inc. (“MediBeacon”), a medical technology company specializing in ...

2 months ago - GlobeNewsWire

MediBeacon® Next Generation TGFR™ System Receives FDA Approval

NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that MediBeacon Inc. (“MediBeacon”), a medical technology company specializing in ...

4 months ago - GlobeNewsWire

INNOVATE Earnings Call Transcript: Q3 2025

Q3 2025 revenue rose 43% year-over-year to $347.1M, led by infrastructure and life sciences growth, while net loss narrowed. DBM Global's backlog and R2's international sales surged, and MediBeacon secured key regulatory approval in China.

5 months ago - Transcripts

INNOVATE Corp. Announces Third Quarter 2025 Results

- Infrastructure: DBM Global delivers robust revenue growth, reinforcing market leadership - - Life Sciences: MediBeacon received regulatory approval to sell the Transdermal GFR System in China - - Sp...

5 months ago - GlobeNewsWire

INNOVATE Corp. to Report Third Quarter 2025 Results on November 12th

NEW YORK, Oct. 22, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that it will release its financial results for the third quarter 2025 on Wednesday...

6 months ago - GlobeNewsWire

MediBeacon receives regulatory approval to sell the Transdermal GFR System in China

NEW YORK, Oct. 21, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that MediBeacon Inc., a medical technology company specializing in the advancement...

6 months ago - GlobeNewsWire

INNOVATE's Portfolio Company, R2, has Explosive Growth and Global Reach with Glacial® Skin Continuing to Redefine Aesthetic Innovation

NEW YORK, Sept. 09, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) today announced that R2 Technologies, Inc. (“R2”), the innovators behind the breakthrough Glacial...

8 months ago - GlobeNewsWire

INNOVATE Earnings Call Transcript: Q2 2025

Q2 2025 saw a 22.7% revenue decline and a net loss of $22 million, driven by lower infrastructure and Spectrum results, partially offset by strong Life Sciences growth. Strategic refinancing extended debt maturities, while DBM Global and R2 maintained robust backlogs and positive outlooks.

9 months ago - Transcripts

INNOVATE Corp. Announces Second Quarter 2025 Results

- Infrastructure: Improved financial flexibility with recent refinancing transactions - - Life Sciences: R2 continuing to see significant year over year growth in system unit sales - - Spectrum: Launc...

9 months ago - GlobeNewsWire

INNOVATE Closes Indebtedness Refinancing Transactions

NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) today announced that it has closed a series of previously announced indebtedness refinancing trans...

9 months ago - GlobeNewsWire

INNOVATE Announces Early Results of Exchange Offer of Senior Secured Notes and Solicitation of Consents and Extends Availability of Total Early Exchange Consideration

NEW YORK, July 31, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) today announced the early participation results as of 5:00 p.m., New York City time, on July 30, 2...

9 months ago - GlobeNewsWire

INNOVATE Corp. to Report Second Quarter 2025 Results on August 5th

NEW YORK, July 17, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that it will release its financial results for the second quarter 2025 on Tuesday,...

10 months ago - GlobeNewsWire

INNOVATE Launches Indebtedness Refinancing Transactions

$48.7 million privately negotiated convertible notes exchanges.$330 million exchange offer of senior secured notes and solicitation of consentsAgreement in principle to extend revolving credit agreeme...

10 months ago - GlobeNewsWire

DBM Global Enters Into an Amended and Restated Credit Agreement

NEW YORK, May 20, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that DBM Global Inc. (“DBMG”), has entered into an amended and restated credit agre...

1 year ago - GlobeNewsWire

INNOVATE Earnings Call Transcript: Q1 2025

Q1 2025 revenue fell 13% year-over-year to $274.2 million, with adjusted EBITDA at $7.2 million and a net loss of $24.8 million. Infrastructure backlog reached $1.4 billion, life sciences saw strong R2 growth, and Spectrum advanced new tech initiatives.

1 year ago - Transcripts

INNOVATE Corp. Announces First Quarter 2025 Results

- Infrastructure: DBM Global first quarter revenue of $264.9 million - - Life Sciences: MediBeacon ® Transdermal GFR (“TGFR”) System Received FDA Approval to Assess Kidney Function - - Spectrum: Expec...

1 year ago - GlobeNewsWire

INNOVATE Corp. to Report First Quarter 2025 Results on May 6th

NEW YORK, April 16, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that it will release its financial results for the first quarter 2025 on Tuesday,...

1 year ago - GlobeNewsWire

INNOVATE Earnings Call Transcript: Q4 2024

Q4 2024 revenue fell 34.5% year-over-year to $236.6M, with adjusted EBITDA at $15M. Life sciences and Spectrum segments saw strong growth, while infrastructure faced project delays but maintained a robust backlog. Total debt was reduced by $54.5M year-over-year.

1 year ago - Transcripts

INNOVATE Corp. Announces Fourth Quarter and Full Year 2024 Results

- Infrastructure: DBM Global fourth quarter revenue of $225.7 million - - Life Sciences: MediBeacon ® Transdermal GFR (“TGFR”) system received FDA approval to assess kidney function - - Spectrum: Broa...

1 year ago - GlobeNewsWire